The Patent Finder
RT

Roche TCRC, Inc.

First filing 2016
OverviewNotableFeesChangesPatent listSources & methods

0 patents currently held, every record listed here

4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

This portfolio holds none of the 4 US patents in force on its record. from the record

Of the 4 now held by other companies, 2 were conveyed to Hoffmann la Roche Inc. in the filing they arrived in, and 2 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end

When these terms end

Each bar runs from grant to computed term end. 2019 to 2042.
US 11,760,807 GPC3-Targeting Drug Which Is Administered To Patient Responsive To GPC3-Targeting Drug Therapy May 8, 2035
US 10,265,279 Combinations of LSD1 Inhibitors for Use in the Treatment of Solid Tumors Mar 14, 2037
US 12,729,243 Dosing for Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibody Apr 29, 2042
US 12,195,547 Dosing for Combination Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibody and ANTI-CD79B Antibody Drug Conjugate Apr 29, 2042
20242029203420392042
4 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2035.
Ends May 2035 · High confidence
Also notable
The largest patent family in this portfolio, 7 related applications, renewed at 2 of 3 maintenance windows. Protection runs to 2037.
conveyed to Hoffmann la Roche Inc. - now held by Oryzon Genomics, S.A.
Ends Mar 2037 · High confidence
Also notable Ends Apr 2042 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

  • 1 of the patents on this record was granted since Aug 17, 2026

Patents held now

Soonest term end first.
Also on record: 4 patents in force now held by others · 4 applications pending · 5 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited